Texas SB1827 regulates investigational stem cell treatments, setting conditions for their administration and oversight.

Texas SB1827 amends the Health and Safety Code to regulate investigational stem cell treatments. These treatments must meet specific conditions, such as being affiliated with a medical school or a hospital with at least 150 beds, or being accredited by certain organizations. The bill also mandates that treatments be administered by certified physicians and overseen by institutional review boards. Additionally, it requires these boards to submit annual reports on adverse events to the Texas Medical Board, ensuring transparency while protecting patient privacy.

Texas SB1827 regulates investigational stem cell treatments, setting conditions for their administration and oversight.

Texas SB1827 amends the Health and Safety Code to regulate investigational stem cell treatments. These treatments must meet specific conditions, such as being affiliated with a medical school or a hospital with at least 150 beds, or being accredited by certain organizations. The bill also mandates that treatments be administered by certified physicians and overseen by institutional review boards. Additionally, it requires these boards to submit annual reports on adverse events to the Texas Medical Board, ensuring transparency while protecting patient privacy.